Market Overview

Avadel Pharmaceuticals Reports Second Quarter 2018 Financial Results

Share:

DUBLIN, Ireland, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on providing innovative medicines for chronic urological, central nervous system, and sleep disorders, today announced its financial results for the second quarter of 2018.

Mike Anderson, Avadel's Chief Executive Officer, said, "Our second quarter was a period of continued investment and focus on building the foundation that is expected to propel us forward into the future. We came in above consensus with $29 million in revenues, largely from our generic hospital products, and have transformed our investment focus to growth-oriented products that have the potential to deliver long-term shareholder value. We are adequately capitalized to continue this transformation, and over the next 12 - 18 months we expect to accelerate our two near-term growth catalysts, NOCTIVA™ and FT 218."

Mr. Anderson continued, "We are just a few months into the launch of NOCTIVA, and although net revenue to date is just under one million dollars, we are encouraged with a number of early indicators of positive traction, including prescription demand, active prescribers, and product awareness levels. More than 2,600 prescriptions have been written to date. We have had positive physician reception with more than 1,000 unique prescribers and our unaided brand-awareness level has reached over 60% in just a few short months. Education and increasing the relevance of nocturia as a condition to be treated in and of itself, and improving coverage and patient access, particularly in Part D, are keys to translating this demand into improved revenue numbers and accelerating NOCTIVA's growth over the next 12-18 months."

"Additionally, we continue to improve recruitment efforts for our REST-ON Phase III trial of our investigational FT 218 drug in patients with narcolepsy. As we enter the second half of this year, we are approximately 50% enrolled. With the FDA's recent agreement to allow the inclusion of a select group of former sodium oxybate users, we have initiated a database review program across our clinical sites.  We have also implemented a new patient referral program and, over the next few months, we will be adding seven new clinical sites in the U.S., and three in Australia where sodium oxybate is not currently available to patients. We have only been fully operational in our initial U.S. sites for about a year and are confident that these additional measures should continue to improve the enrollment rate for the second half of our study," concluded Mr. Anderson.

Overview of second quarter 2018 financial results:

Revenues:        
    Three Months Ended June 30,
($ in 000s) By Product   2018   2017
         
Bloxiverz   $ 5,544     $  13,719  
Vazculep    11,377     10,154  
Akovaz   11,875     20,912  
Noctiva   289      
Other   31     2,320  
Product sales   29,116     47,105  
License revenue                                                                                        114     (794 )
Total revenues   $     29,230     $ 46,311  
 

Revenues for the second quarter 2018 were $29.2 million, compared to $46.3 million in the second quarter 2017. The decline on a year-over-year basis was attributed to lower net selling prices and units shipped for Bloxiverz® and Akovaz® due to more competition, slightly offset by higher Vaculep® revenues from increased units shipped during the second quarter 2018. Net sales for NOCTIVA were $289,000 in the second quarter 2018, down on a quarter-over-quarter basis from $666,000 due largely to the initial wholesaler stocking that occurred at the end of the first quarter 2018 in anticipation of the May 2018 branded launch.

Operating expenses:        
    Three Months Ended June 30,
($ in 000s) Operating expenses   2018   2017
         
Cost of products   $ 3,512     $ 4,561  
Research and development expenses (R&D)   11,890     6,792  
Selling, general and administrative expenses (SG&A)                              27,843     12,429  
             

R&D expense was up 75% in the second quarter 2018 compared to the prior year period, primarily due to increased spend on the Phase III REST-ON trial. The $15.5 million increase in SG&A in the second quarter 2018 compared to the second quarter 2017 was due to sales and marketing expenses associated with the launch of NOCTIVA.

GAAP earnings:        
    Three Months Ended June 30,
($ in 000s except for per share)   2018   2017
         
Net (loss) income   $ (3,438 )   $ 28,927
Net (loss) income per share - diluted                                                        (0.09 )   0.68
           

Included in GAAP net loss for the second quarter 2018 were gains of $12.9 million related to changes in the fair value of related party contingent consideration, compared to gains of $13.2 million in the same period last year. These non-cash gains were recorded as a result of reducing the fair value of related party contingent consideration due to changing market conditions across the Company's three hospital products.

Adjusted earnings (1):        
    Three Months Ended June 30,
($ in 000s except for per share)   2018   2017
         
Net (loss) income   $ (20,261 )   $ 8,165  
Net (loss) income per share - diluted                                                      (0.55 )   0.19  
             
(1)  Descriptions of Avadel's non-GAAP financial measures are included under the caption Non-GAAP Disclosures and Adjustments included within this press release and reconciliations of such non-GAAP financial measures to their most closely applicable GAAP financial measures are found in the Supplemental Information section herein.
 

The decrease in adjusted net income is largely attributable to lower revenues from the Company's hospital products and higher SG&A due to the 2018 launch of Noctiva.  Please see the Supplemental Information section within this document for a reconciliation of adjusted net income and adjusted diluted EPS to the respective GAAP amounts.

2018 Guidance:

The Company maintained its full year 2018 spend guidance for R&D of between $40 to $50 million, and SG&A of between $80 to $90 million. Cash interest expense as a result of the Company's convertible notes offering in February 2018 is expected to be approximately $6 million, and a non-GAAP tax benefit of 0% to 10%  of loss before tax is  anticipated for the full year 2018. During the second quarter competing products were approved for Vazculep, Bloxiverz and NOCTIVA; as such, the Company is lowering its full year revenue guidance to a range of $90 to $105 million from $105 to $125 million. Included in this range is an estimated $5 to $10 million in revenue from NOCTIVA, down from previous guidance of $10 to $20 million, in part due to a lower than expected net-realized selling price from a less favorable mix of commercially insured to Medicare Part D prescriptions in the initial launch period. The Company expects an increase in net-selling price as it continues to improve script volume and market access throughout the course of the next 12 to 18 months.

Conference Call:

A conference call to discuss these results has been scheduled for Tuesday, August 7, 2018 at 10:00 a.m. EDT. A question and answer period will follow management's prepared remarks. To access the conference call, investors are invited to dial (844) 388-0559 (U.S. and Canada) or (216) 562-0393 (International). The conference ID number is 7367859. A live audio webcast can be accessed by visiting the Investors section of the Company's website, www.avadel.com. A replay of the webcast will be archived on Avadel's website for 90 days following the event.

About Avadel Pharmaceuticals plc:

Avadel Pharmaceuticals plc (NASDAQ:AVDL) is a specialty pharmaceutical company that seeks to develop differentiated pharmaceutical products that are safe, effective and easy to take through formulation development, by utilizing its proprietary drug delivery technology and through in-licensing / acquiring new products; ultimately, helping patients adhere to their prescribed medical treatment and see better results. Avadel's current portfolio of products and product candidates focuses on the urology, central nervous system (CNS) / sleep, and hospital markets. The Company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France. For more information, please visit www.avadel.com.

Safe Harbor: This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words "will," "may," "believe," "expect," "anticipate," "estimate," "project" and similar expressions, and the negatives thereof, identify forward-looking statements, each of which speaks only as of the date the statement is made. Although we believe that our forward-looking statements are based on reasonable assumptions within the bounds of our knowledge of our business and operations, our business is subject to significant risks and as a result there can be no assurance that actual results of our research, development and commercialization activities and our results of operations will not differ materially from the results contemplated in such forward-looking statements. These risks include: (i) risks relating to our exchangeable senior notes including use of the net proceeds from the offering of the notes and other future events related to the notes; (ii) risks relating to the divestiture of our former pediatric business including whether such divestiture will be accretive to our operating income and cash flow; (iii) risks relating to our license agreement with Serenity Pharmaceuticals, LLC including that a potential competitive product, and patent litigation with the manufacturer of that product, could have a material adverse impact on our ability to successfully exploit any market opportunity for the drug desmopressin acetate (the "Drug") which we are marketing under the brand name Noctivatm, our internal analyses may overstate the market opportunity in the United States for the Drug or we may not effectively exploit such market opportunity, that significant safety or drug interaction problems could arise with respect to the Drug, that we may not successfully increase awareness of nocturia and the potential benefits of the Drug, and that the need for management to focus attention on the development and commercialization of the Drug could cause our ongoing business operations to suffer; and (iv) the other risks, uncertainties and contingencies described in the Company's filings with the U.S. Securities and Exchange Commission, including our annual report on Form 10-K for the year ended December 31, 2017, in particular disclosures that may be set forth in particular under the captions "Forward-Looking Statements" and "Risk Factors," including without limitation: our dependence on a small number of products and customers for the majority of our revenues; the possibility that our Bloxiverz®,Vazculep® and Akovaz® products, which are not patent protected, could face substantial competition resulting in a loss of market share or forcing us to reduce the prices we charge for those products; the possibility that we could fail to successfully complete the research and development for pipeline products we are evaluating for potential application to the FDA pursuant to our "unapproved-to-approved" strategy, or that competitors could complete the development of such products and apply for FDA approval of such products before us; the possibility that our products may not reach the commercial market or gain market acceptance; our need to invest substantial sums in research and development in order to remain competitive; our dependence on certain single providers for development of several of our drug delivery platforms and products; our dependence on a limited number of suppliers to manufacture our products and to deliver certain raw materials used in our products; the possibility that our competitors may develop and market technologies or products that are more effective or safer than ours, or obtain regulatory approval and market such technologies or products before we do; the challenges in protecting the intellectual property underlying our drug delivery platforms and other products; and our dependence on key personnel to execute our business plan.

Non-GAAP Disclosures and Adjustments

Avadel discloses certain non-GAAP financial measures, including adjusted net income and loss and adjusted net income and loss per diluted share, as management believes that such non-GAAP financial measures can enhance an overall understanding of the Company's financial performance when considered together with financial measures prepared in accordance with generally accepted accounting principles (GAAP) in the U.S. In addition to reporting its financial results in accordance with GAAP, Avadel reports certain non-GAAP results that exclude, if any, fair value remeasurements of its contingent consideration, amortization of debt discount and debt issuance costs attributable to our  exchangeable notes, impairment of intangible assets, if any, amortization of intangible assets, restructuring costs, if any, foreign exchange gains and losses on assets and liabilities denominated in foreign currencies, unrealized gains/losses on marketable equity securities,  but includes the cash payments plus any unpaid accrued cash payments associated with the contingent consideration and cash interest payments or related accruals on the exchangeable notes. The Company's management uses these non-GAAP measures internally for forecasting, budgeting and measuring its operating performance. Investors and other readers should review the related GAAP financial measures and the reconciliation of non-GAAP measures to their most closely comparable GAAP measure set forth below and should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP. The table provided within the following "Supplemental Information" section reconciles GAAP net income and loss and diluted earnings or loss per share to the corresponding adjusted amounts.

 

Contacts: Michael F. Kanan
  Chief Financial Officer
  Phone: (636) 449-1844
  Email: mkanan@avadel.com
   
  Lauren Stival
  Sr. Director, Investor Relations & Corporate Communications
  Phone: (636) 449-5866
  Email: lstival@avadel.com
   
   
   

AVADEL PHARMACEUTICALS PLC
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS)
(In thousands, except per share data)

    Three Months Ended June 30,   Six Months Ended June 30,
    2018   2017     2018   2017
                 
Revenues:                
Product sales   $ 29,116     $ 47,105     $ 62,277     $ 98,862  
License revenue   114     (794 )   246     (44 )
Total revenues   29,230     46,311     62,523     98,818  
Operating expenses:                
Cost of products   3,512     4,561     10,104     8,463  
Research and development expenses   11,890     6,792     21,841     13,998  
Selling, general and administrative expenses   27,843     12,429     52,330     24,241  
Intangible asset amortization   1,609     564     3,376     1,128  
Gain - changes in fair value of related party contingent consideration   (12,889 )   (13,230 )   (9,921 )   (20,201 )
Restructuring costs   50     1,069     203     3,722  
Total operating expenses   32,015     12,185     77,933     31,351  
Operating (loss) income   (2,785 )   34,126     (15,410 )   67,467  
Investment and other income (expense), net   583     764     637     1,585  
Interest expense, net   (2,980 )   (263 )   (4,577 )   (526 )
Other income - changes in fair value of related party payable   1,402     1,670     1,007     2,220  
(Loss) income before income taxes   (3,780 )   36,297     (18,343 )   70,746  
Income tax (benefit) provision   (342 )   7,370     (2,669 )   15,909  
Net (loss) income   $ (3,438 )   $ 28,927     $ (15,674 )   $ 54,837  
                 
Net (loss) income per share - basic   $ (0.09 )   $ 0.70     $ (0.42 )   $ 1.33  
Net (loss) income per share - diluted   (0.09 )   0.68     (0.42 )   1.29  
                 
Weighted average number of shares outstanding - basic   36,772     41,091     37,666     41,233  
Weighted average number of shares outstanding - diluted   36,772     42,487     37,666     42,625  

AVADEL PHARMACEUTICALS PLC
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except per share data)

    June 30, 2018     December 31, 2017
         
ASSETS        
Current assets:        
Cash and cash equivalents   $ 12,477     $ 16,564  
Marketable securities                        134,629     77,511  
Accounts receivable   14,940     14,785  
Inventories   5,724     6,157  
Prepaid expenses and other current assets   7,206     8,958  
Total current assets   174,976     123,975  
Property and equipment, net   2,439     3,001  
Goodwill   18,491     18,491  
Intangible assets, net   70,962     92,289  
Research and development tax credit receivable   6,124     5,272  
Other non-current assets   22,244     10,249  
Total assets   $ 295,236     $ 253,277  
         
LIABILITIES AND SHAREHOLDERS' EQUITY        
Current liabilities:        
Current portion of long-term debt   $ 108     $ 111  
Current portion of long-term related party payable   14,067     25,007  
Accounts payable   11,169     7,477  
Deferred revenue   1,724     2,007  
Accrued expenses   21,493     50,926  
  Other current liabilities   3,052     1,011  
Total current liabilities   51,613     86,539  
Long-term debt, less current portion   113,038     156  
Long-term related party payable, less current portion   38,050     73,918  
Other non-current liabilities   13,989     7,084  
Total liabilities   216,690     167,697  
         
Shareholders' equity:          
Preferred shares, $0.01 nominal value; 50,000 shares authorized at June 30, 2018 and December 31, 2017, respectively; none issued or outstanding at June 30, 2018 and December 31, 2017, respectively        
Ordinary shares, nominal value of $0.01; 500,000 shares authorized; 42,148 issued and 36,740 outstanding at June 30, 2018 and 41,463 issued and 39,346 outstanding at December 31, 2017   421     414  
Treasury shares, at cost, 5,408 and 2,117 shares held at June 30, 2018 and December 31, 2017, respectively   (49,998 )   (22,361 )
Additional paid-in capital   430,141     393,478  
Accumulated deficit   (278,359 )   (262,685 )
Accumulated other comprehensive loss   (23,659 )   (23,266 )
Total shareholders' equity   78,546     85,580  
Total liabilities and shareholders' equity   $ 295,236     $ 253,277  
 
 
 

AVADEL PHARMACEUTICALS PLC
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)

  Six Months Ended June 30,
  2018   2017
       
Cash flows from operating activities:      
Net (loss) income $ (15,674 )   $ 54,837  
Adjustments to reconcile net (loss) income to net cash provided by operating activities:      
Depreciation and amortization 3,810     1,611  
Amortization of premiums on marketable securities 1,693     34  
Foreign exchange loss (160 )   1,304  
Remeasurement of related party acquisition-related contingent consideration (9,921 )   (20,201 )
Remeasurement of related party financing-related contingent consideration (1,007 )   (2,220 )
Amortization of debt discount and debt issuance costs 2,019      
Change in deferred tax and income tax deferred charge (3,247 )   322  
Stock-based compensation expense 4,358     4,055  
Other adjustments 251     (115 )
Net changes in assets and liabilities      
Accounts receivable (157 )   (1,446 )
Inventories (242 )   (2,489 )
Prepaid expenses and other current assets 1,587     (264 )
Research and development tax credit receivable (1,003 )   (1,175 )
Accounts payable & other current liabilities 5,206     4,931  
Accrued expenses (9,831 )   12,747  
Earn-out payments for related party contingent consideration in excess of acquisition-date fair value (11,113 )   (16,515 )
Royalty payments for related party payable in excess of original fair value (1,618 )   (2,287 )
Other assets and liabilities (2,893 )   407  
Net cash (used in) provided by operating activities (37,942 )   33,536  
       
Cash flows from investing activities:      
Purchases of property and equipment (99 )   (321 )
Purchase of intangible asset (20,000 )    
Proceeds from sales of marketable securities 253,525     51,820  
Purchases of marketable securities (312,638 )   (67,743 )
Net cash used in investing activities (79,212 )   (16,244 )
       
Cash flows from financing activities:      
Earn-out payments for related party contingent consideration (645 )   (665 )
Proceeds from debt issuance 143,750      
Payments for debt issuance costs (5,760 )    
Share repurchases (27,637 )   (13,081 )
Cash proceeds from the issuance of ordinary shares and warrants 3,446     376  
Other financing activities, net 6     12  
Net cash provided by (used in) financing activities 113,160     (13,358 )
       
Effect of foreign currency exchange rate changes on cash and cash equivalents (93 )   358  
       
Net change in cash and cash equivalents (4,087 )   4,292  
Cash and cash equivalents at January 1, 16,564     39,215  
Cash and cash equivalents at June 30, $ 12,477     $ 43,507  

AVADEL PHARMACEUTICALS PLC
UNAUDITED SUPPLEMENTAL INFORMATION
(In thousands, except per share data)

    Three Months Ended June 30,     Six Months Ended June 30,
Revenues by Product:     2018   2017   2018   2017
                 
Bloxiverz   $ 5,544     $ 13,719     $ 13,035     $ 27,621  
Vazculep   11,377     10,154     24,338     20,334  
Akovaz   11,875     20,912     22,092     46,549  
Noctiva   289         955      
Other   31     2,320     1,857     4,358  
Total product sales   29,116     47,105     62,277     98,862  
License revenue                                                                              114     (794 )   246     (44 )
Total revenues   $ 29,230     $ 46,311     $ 62,523     $ 98,818  
 
 


      GAAP to Non-GAAP adjustments for the three-months ended June 30, 2018                
      Exclude       Include        
  GAAP     Intangible asset
amortization
      Foreign exchange
(gain)/loss
      Restructuring
impacts
    Equity securities
unrealized
(gain)/loss impact
      Amortization of debt
discount and
debt issuance costs
      Contingent related
party payable fair
value remeasurements
  Contingent related
party payable
paid/accrued
  Total
adjustments
  Adjusted GAAP
                                       
Revenues:                                      
Product sales $ 29,116     $     $     $     $     $     $     $     $     $ 29,116  
License revenue 114                                     114  
Total revenues 29,230                                     29,230  
Operating expenses:                                      
Cost of products 3,512                                     3,512  
Research and development expenses 11,890                                     11,890  
Selling, general and administrative expenses 27,843                                     27,843  
Intangible asset amortization 1,609     (1,609 )                           (1,609 )    
Loss (gain) - changes in fair value of related party contingent
consideration
(12,889 )                       12,889     5,060     17,949     5,060  
Restructuring costs 50             (50 )                   (50 )    
Total operating expenses 32,015     (1,609 )       (50 )           12,889     5,060     16,290     48,305  
Operating (loss) income (2,785 )   1,609         50             (12,889 )   (5,060 )   (16,290 )   (19,075 )
Investment and other income
(expense), net
583         7         (112 )               (105 )   478  
Interest expense, net (2,980 )                   1,363             1,363     (1,617 )
Other expense (income) -
changes in fair value of related
party payable
1,402                         (1,402 )   (751 )   (2,153 )   (751 )
(Loss) income before income
taxes
(3,780 )   1,609     7     50     (112 )   1,363     (14,291 )   (5,811 )   (17,185 )   (20,965 )
Income tax (benefit) provision (342 )   338             (2 )       (471 )   (227 )   (362 )   (704 )
Net (loss) income $ (3,438 )   $ 1,271     $ 7     $ 50     $ (110 )   $ 1,363     $ (13,820 )   $ (5,584 )   $ (16,823 )   $ (20,261 )
                                       
Net income (loss) per share - diluted(1) $ (0.09 )   $ 0.03     $     $     $     $ 0.04     $ (0.38 )   $ (0.15 )   $ (0.46 )   $ (0.55 )
Weighted average number of
shares outstanding - diluted
36,772     36,772     36,772     36,772     36,772     36,772     36,772     36,772     36,772     36,772  

(1)  Net income (loss) per share - diluted is calculated by dividing Net income (loss) by the Weighted average number of shares outstanding - diluted. Note, when recalculated using this method, the balances in the Total adjustment and Adjusted GAAP columns may not cross-foot as a result of rounding to full precision.

 

 
      GAAP to Non-GAAP adjustments for the three-months ended June 30, 2017        
      Exclude   Include        
  GAAP   Intangible asset
amortization
  Foreign exchange
(gain)/loss
  Restructuring
impacts
  License revenue
adjustment
  Contingent related party
payable fair value
remeasurements
  Contingent related
party payable
paid/accrued
  Total
adjustments
  Adjusted
GAAP
                                   
Revenues:                                  
Product sales $ 47,105     $     $     $     $     $     $     $     $ 47,105  
License revenue (794 )               1,100             1,100     306  
Total revenues 46,311                 1,100             1,100     47,411  
Operating expenses:                                  
Cost of products 4,561                                 4,561  
Research and development expenses 6,792                                 6,792  
Selling, general and administrative expenses 12,429                                 12,429  
Intangible asset amortization 564     (564 )                       (564 )    
Loss (gain) - changes in fair value of related party contingent consideration (13,230 )                   13,230     8,516     21,746     8,516  
Restructuring costs 1,069             (1,069 )               (1,069 )    
Total operating expenses 12,185     (564 )       (1,069 )       13,230     8,516     20,113     32,298  
Operating (loss) income 34,126     564         1,069     1,100     (13,230 )   (8,516 )   (19,013 )   15,113  
Investment and other income (expense), net 764         (237 )                   (237 )   527  
Interest expense, net (263 )                               (263 )
Other expense (income) - changes in fair value of related party payable 1,670                     (1,670 )   (1,166 )   (2,836 )   (1,166 )
(Loss) income before income taxes 36,297     564     (237 )   1,069     1,100     (14,900 )   (9,682 )   (22,086 )   14,211  
Income tax (benefit) provision 7,370     201                 (909 )   (616 )   (1,324 )   6,046  
Net (loss) income $ 28,927     $ 363     $ (237 )   $ 1,069     $ 1,100     $ (13,991 )   $ (9,066 )   $ (20,762 )   $ 8,165  
                                   
Net income (loss) per share - diluted(1) $ 0.68     $ 0.01     $ (0.01 )   $ 0.03     $ 0.03     $ (0.33 )   $ (0.21 )   $ (0.49 )   $ 0.19  
Weighted average number of shares outstanding - diluted 42,487     42,487     42,487     42,487     42,487     42,487     42,487     42,487     42,487  

(1) Net income (loss) per share - diluted is calculated by dividing Net income (loss) by the Weighted average number of shares outstanding - diluted. Note, when recalculated using this method, the balances in the Total adjustment and Adjusted GAAP columns may not cross-foot as a result of rounding to full precision.

 

      GAAP to Non-GAAP adjustments for the six-months ended June 30, 2018        
      Exclude   Include        
  GAAP   Intangible asset
amortization
  Foreign exchange
(gain)/loss
  Restructuring
impacts
  Equity securities
unrealized
(gain)/loss impact
  Amortization of
debt discount and
debt issuance costs
  Contingent related
party payable
fair value
remeasurements
  Contingent related
party payable
paid/accrued
  Total
adjustments
  Adjusted
GAAP
                                                     
Revenues:                                      
Product sales $ 62,277     $     $     $     $     $     $     $     $     $ 62,277  
License revenue 246                                     246  
Total revenues 62,523                                     62,523  
Operating expenses:                                      
Cost of products 10,104                                     10,104  
Research and development expenses 21,841                                     21,841  
Selling, general and administrative expenses 52,330                                     52,330  
Intangible asset amortization 3,376     (3,376 )                           (3,376 )    
Loss (gain) - changes in fair value of related party contingent consideration (9,921 )                       9,921     10,850     20,771     10,850  
Restructuring costs 203             (203 )                   (203 )    
Total operating expenses 77,933     (3,376 )       (203 )           9,921     10,850     17,192     95,125  
Operating (loss) income (15,410 )   3,376         203             (9,921 )   (10,850 )   (17,192 )   (32,602 )
Investment and other income (expense), net 637         (160 )       186                 26     663  
Interest expense, net (4,577 )                   2,019             2,019     (2,558 )
Other expense (income) - changes in fair value of related party payable 1,007                         (1,007 )   (1,548 )   (2,555 )   (1,548 )
(Loss) income before income taxes (18,343 )   3,376     (160 )   203     186     2,019     (10,928 )   (12,398 )   (17,702 )   (36,045 )
Income tax (benefit) provision (2,669 )   709             (5 )       (348 )   (473 )   (117 )   (2,786 )
Net (loss) income $ (15,674 )   $ 2,667     $ (160 )   $ 203     $ 191     $ 2,019     $ (10,580 )   $ (11,925 )   $ (17,585 )   $ (33,259 )
                                       
Net income (loss) per share - diluted(1) $ (0.42 )   $ 0.07     $     $ 0.01     $ 0.01     $ 0.05     $ (0.28 )   $ (0.32 )   $ (0.47 )   $ (0.88 )
Weighted average number of shares outstanding - diluted 37,666     37,666     37,666     37,666     37,666     37,666     37,666     37,666     37,666     37,666  
                                                           
                                                           


      GAAP to Non-GAAP adjustments for the six-months ended June 30, 2017        
      Exclude   Include        
  GAAP   Intangible asset
amortization
  Foreign
exchange
(gain)/loss
  Restructuring
impacts
  Purchase
accounting
adjustments - FSC
  License revenue
adjustment
  Contingent related
party payable fair
value remeasurements
  Contingent related
party payable
paid/accrued
  Total
adjustments
  Adjusted
GAAP
                                       
Revenues:                                      
Product sales $ 98,862     $     $         $     $     $     $     $     $ 98,862  
License revenue (44 )                   1,100             1,100     1,056  
Total revenues 98,818                     1,100             1,100     99,918  
Operating expenses:                                      
Cost of products 8,463                 (46 )               (46 )   8,417  
Research and development expenses 13,998                                     13,998  
Selling, general and administrative expenses 24,241                                     24,241  
Intangible asset amortization 1,128     (1,128 )                           (1,128 )    
Loss (gain) - changes in fair value of related party contingent consideration (20,201 )                       20,201     18,132     38,333     18,132  
Restructuring costs 3,722             (3,722 )                   (3,722 )    
Total operating expenses 31,351     (1,128 )       (3,722 )   (46 )       20,201     18,132     33,437     64,788  
Operating (loss) income 67,467     1,128         3,722     46     1,100     (20,201 )   (18,132 )   (32,337 )   35,130  
Investment and other income (expense), net 1,585         (6 )                       (6 )   1,579  
Interest expense, net (526 )                                   (526 )
Other expense (income) - changes in fair value of related party payable 2,220                         (2,220 )   (2,465 )   (4,685 )   (2,465 )
(Loss) income before income taxes 70,746     1,128     (6 )   3,722     46     1,100     (22,421 )   (20,597 )   (37,028 )   33,718  
Income tax (benefit) provision 15,909     402             17         (1,269 )   (1,307 )   (2,157 )   13,752  
Net (loss) income $ 54,837     $ 726     $ (6 )   3,722     $ 29     $ 1,100     $ (21,152 )   $ (19,290 )   $ (34,871 )   $ 19,966  
                                       
Net income (loss) per share - diluted(1) $ 1.29     $ 0.02     $     0.09     $     $ 0.03     $ (0.50 )   $ (0.45 )   $ (0.82 )   $ 0.47  
Weighted average number of shares outstanding - diluted 42,625     42,625     42,625     42,625     42,625     42,625     42,625     42,625     42,625     42,625  

(1)  Net income (loss) per share - diluted is calculated by dividing Net income (loss) by the Weighted average number of shares outstanding - diluted. Note, when recalculated using this method, the balances in the Total adjustment and Adjusted GAAP columns may not cross-foot as a result of rounding to full precision.

Primary Logo

View Comments and Join the Discussion!